Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
暂无分享,去创建一个
[1] R. Wade-Martins,et al. Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease , 2019, Front. Mol. Neurosci..
[2] Andrew J. Lees,et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial , 2018 .
[3] M. Terpstra,et al. Repeated‐Dose Oral N‐Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress , 2018, Journal of clinical pharmacology.
[4] J. Kordower,et al. Therapeutic approaches to target alpha-synuclein pathology , 2017, Experimental Neurology.
[5] A. Ascherio,et al. Targeting urate to reduce oxidative stress in Parkinson disease , 2017, Experimental Neurology.
[6] K. Kieburtz,et al. Clinical approaches to the development of a neuroprotective therapy for PD , 2017, Experimental Neurology.
[7] J. Obeso,et al. Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification , 2017, Experimental Neurology.
[8] A. West. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease , 2017, Experimental Neurology.
[9] Subhojit Roy. Synuclein and dopamine: the Bonnie and Clyde of Parkinson's disease , 2017, Nature Neuroscience.
[10] A. Lang,et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD) , 2017, Neurology.
[11] Does smoking impact dopamine neuronal loss in de novo Parkinson disease? , 2017, Annals of neurology.
[12] Xia Shen,et al. Long-term effects of exercise and physical therapy in people with Parkinson disease , 2017, Nature Reviews Neurology.
[13] R. Kalb,et al. Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration , 2017, Nature Neuroscience.
[14] M. Hallett,et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[15] David S. Park,et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease , 2017, Science.
[16] A. West,et al. LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model , 2017, Molecular therapy. Nucleic acids.
[17] C. Zurzolo,et al. α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading , 2017, Acta Neuropathologica.
[18] L. Defebvre,et al. New perspectives on study designs for evaluating neuroprotection in Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[19] C. Kemp,et al. Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional Restoration , 2017, The Journal of Neuroscience.
[20] Ronan M. T. Fleming,et al. Embryonic development of selectively vulnerable neurons in Parkinson’s disease , 2017, npj Parkinson's Disease.
[21] J. Volkmann,et al. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model , 2017, Annals of neurology.
[22] R. Mailman,et al. Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database , 2017, Movement disorders : official journal of the Movement Disorder Society.
[23] Katie Kingwell. Zeroing in on neurodegenerative α-synuclein , 2017, Nature Reviews Drug Discovery.
[24] E. Tan,et al. Targeting LRRK2 in Parkinson’s disease: an update on recent developments , 2017, Expert opinion on therapeutic targets.
[25] R. Rockhill,et al. A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III) , 2017, Annals of clinical and translational neurology.
[26] S. Lehéricy,et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial , 2017, The Lancet Neurology.
[27] Miia Kivipelto,et al. Can lifestyle changes prevent cognitive impairment? , 2017, The Lancet Neurology.
[28] D. Barrett,et al. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice , 2017, Brain : a journal of neurology.
[29] Nir Giladi,et al. Statin adherence and the risk of Parkinson's disease: A population-based cohort study , 2017, PloS one.
[30] Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial , 2017, npj Parkinson's Disease.
[31] C. Tanner,et al. Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials , 2017, Movement disorders : official journal of the Movement Disorder Society.
[32] R. Sidman,et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models , 2017, Proceedings of the National Academy of Sciences.
[33] D. James Surmeier,et al. Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.
[34] Craig W. Ritchie,et al. Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project , 2017, Alzheimer's & Dementia.
[35] C. Olanow,et al. Targeting α‐Synuclein as a therapy for Parkinson's disease: The battle begins , 2017, Movement disorders : official journal of the Movement Disorder Society.
[36] D. Krainc,et al. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies , 2017, Nature Medicine.
[37] A. Lang,et al. Precision medicine for disease modification in Parkinson disease , 2017, Nature Reviews Neurology.
[38] R. Chung,et al. Potential Modes of Intercellular α-Synuclein Transmission , 2017, International journal of molecular sciences.
[39] T. Montine,et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis , 2017, The Lancet Neurology.
[40] Michele Vendruscolo,et al. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity , 2017, Proceedings of the National Academy of Sciences.
[41] D. Dickson,et al. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration , 2017, Movement disorders : official journal of the Movement Disorder Society.
[42] M. Grundman,et al. First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers , 2016, Movement disorders : official journal of the Movement Disorder Society.
[43] V. Sossi,et al. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient , 2016, Annals of neurology.
[44] Michele Pernia,et al. A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity , 2017 .
[45] R. Barker,et al. Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD). , 2017, Progress in brain research.
[46] R. Chung,et al. Potential Modes of Intercellular Alpha-Synuclein Transmission , 2017 .
[47] M. Tansey,et al. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? , 2017, npj Parkinson's Disease.
[48] Rob Knight,et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease , 2016, Cell.
[49] A. Lang,et al. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era , 2016, Trends in Neurosciences.
[50] T. Foltynie,et al. Challenges in detecting disease modification in Parkinson's disease clinical trials. , 2016, Parkinsonism & related disorders.
[51] Ching-Kuan Liu,et al. Statin therapy prevents the onset of Parkinson disease in patients with diabetes , 2016, Annals of neurology.
[52] R. Barker,et al. Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[53] Ho Chul Kang,et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3 , 2016, Science.
[54] R. Barker,et al. Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[55] Edo Richard,et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial , 2016, The Lancet.
[56] Jaeil Ahn,et al. Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies , 2016, Journal of Parkinson's disease.
[57] Zhenzhen Quan,et al. Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson’s Disease , 2016, Neurochemical Research.
[58] C. Ritchie,et al. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease , 2016, BMC Neurology.
[59] T. Foltynie,et al. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. , 2016, Drug discovery today.
[60] P. Kallunki,et al. Development of Passive Immunotherapies for Synucleinopathies , 2016, Movement disorders : official journal of the Movement Disorder Society.
[61] José Luis Molinuevo,et al. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. , 2016, The lancet. Psychiatry.
[62] E. Masliah,et al. Combination therapies: The next logical Step for the treatment of synucleinopathies? , 2016, Movement disorders : official journal of the Movement Disorder Society.
[63] M. Xilouri,et al. Autophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies , 2016, Movement disorders : official journal of the Movement Disorder Society.
[64] G. Halliday,et al. Neuropathology of α‐synuclein propagation and braak hypothesis , 2016, Movement disorders : official journal of the Movement Disorder Society.
[65] M. Mandler,et al. Active immunization therapies for Parkinson's disease and multiple system atrophy , 2016, Movement disorders : official journal of the Movement Disorder Society.
[66] Suneil K. Kalia,et al. Merging DBS with viral vector or stem cell implantation: “hybrid” stereotactic surgery as an evolution in the surgical treatment of Parkinson’s disease , 2016, Molecular therapy. Methods & clinical development.
[67] A. Lang,et al. Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson’s disease: the LEAP-study , 2015, BMC Neurology.
[68] C. Olanow,et al. Trophic factors for Parkinson's disease: To live or let die , 2015, Movement disorders : official journal of the Movement Disorder Society.
[69] A. Milnerwood,et al. Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease , 2015, The Lancet Neurology.
[70] Lauren Heusinkveld,et al. Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson's disease. , 2015, Parkinsonism & related disorders.
[71] Günther Deuschl,et al. MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[72] Elliott W. Dirr,et al. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration , 2015, Neurobiology of Disease.
[73] Suneil K. Kalia,et al. Disease‐modifying strategies for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[74] Christer Halldin,et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. , 2015, Brain : a journal of neurology.
[75] R. Barker,et al. Cell-based therapies for Parkinson disease—past insights and future potential , 2015, Nature Reviews Neurology.
[76] J. Jankovic,et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial , 2015, Annals of neurology.
[77] Lars Bäckman,et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial , 2015, The Lancet.
[78] Mark R Cookson,et al. LRRK2 Pathways Leading to Neurodegeneration , 2015, Current Neurology and Neuroscience Reports.
[79] L. Defebvre,et al. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease , 2015, BMC Neurology.
[80] C. Sortwell,et al. Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system , 2015, Experimental Neurology.
[81] Steven Potkin,et al. Building a roadmap for developing combination therapies for Alzheimer’s disease , 2015, Expert review of neurotherapeutics.
[82] R. Youle,et al. The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease , 2015, Neuron.
[83] Michael Krams,et al. Charting a path toward combination therapy for Alzheimer’s disease , 2015, Expert review of neurotherapeutics.
[84] D. Standaert,et al. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. , 2015, Journal of Parkinson's disease.
[85] J. Trojanowski,et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. , 2015, JAMA neurology.
[86] Mancheva-Ganeva Velina,et al. Licensed under Creative Commons Attribution Cc by Oxidative Stress in Parkinson's Disease , 2022 .
[87] O. Hantschel,et al. C-abl Phosphorylates Alpha-synuclein And Regulates Its Degradation, Implication For Alpha-synuclein Clearance And Contribution To The Pathogenesis Of Parkinson's Disease , 2014 .
[88] B. Ritz,et al. Parkinson disease and smoking revisited , 2014, Neurology.
[89] H. Groenewegen,et al. Stage‐dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[90] H. Shill,et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease , 2014, Neurology.
[91] DuhamelAlain,et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .
[92] T. Dawson,et al. The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease , 2014, Scientific Reports.
[93] H. Shill,et al. Concomitant pathologies among a spectrum of parkinsonian disorders. , 2014, Parkinsonism & related disorders.
[94] A. Albanese,et al. Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease? , 2014, Parkinsonism & related disorders.
[95] R. Barker,et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial , 2014, The Lancet.
[96] T. Foltynie,et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells , 2014, Brain : a journal of neurology.
[97] E. Masliah,et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials , 2014, Acta Neuropathologica.
[98] E. Masliah,et al. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. , 2014, Human molecular genetics.
[99] L. Defebvre,et al. Targeting Chelatable Iron as a Therapeutic Modality in Parkinson ’ s Disease , 2016 .
[100] A. Björklund,et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. , 2014, JAMA neurology.
[101] C. Adler,et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. , 2013, Brain : a journal of neurology.
[102] M. Nalls,et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. , 2013, JAMA neurology.
[103] W. Poewe,et al. Trial designs used to study neuroprotective therapy in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[104] Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease , 2013, Neurotherapeutics.
[105] A. Lang,et al. Parkinson's disease subtypes: lost in translation? , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[106] J. Bolam,et al. Living on the edge with too many mouths to feed: Why dopamine neurons die , 2012, Movement disorders : official journal of the Movement Disorder Society.
[107] A. Siderowf,et al. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[108] J. Winkler,et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy , 2012, Experimental Neurology.
[109] P. Starr,et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. , 2012, Human gene therapy.
[110] E. Masliah,et al. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model , 2012, The European journal of neuroscience.
[111] Peter Konrad,et al. Deep brain stimulation in early stage Parkinson's disease: operative experience from a prospective randomised clinical trial , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[112] Honglei Chen,et al. Use of ibuprofen and risk of Parkinson disease , 2011, Neurology.
[113] G. Halliday,et al. Glia: Initiators and progressors of pathology in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[114] J. Stockman. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .
[115] J. Obeso,et al. Dopaminergic transplantation for parkinson's disease: Current status and future prospects , 2009, Annals of neurology.
[116] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[117] A. Siderowf,et al. Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment , 2008, Annals of neurology.
[118] R. Hauser,et al. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.
[119] G. Halliday,et al. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years , 2008, Movement disorders : official journal of the Movement Disorder Society.
[120] Elisabet Englund,et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.
[121] G. Levy,et al. The relationship of Parkinson disease with aging. , 2007, Archives of neurology.
[122] A. Benabid,et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. , 2007, Brain : a journal of neurology.
[123] A. Lang. The progression of Parkinson disease , 2007, Neurology.
[124] R. Palm,et al. Selegiline slows the progression of the symptoms of Parkinson disease , 2006, Neurology.
[125] Mark Stacy,et al. Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.
[126] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[127] H. Federoff,et al. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? , 2005, Brain research. Molecular brain research.
[128] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[129] D W Dickson,et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.
[130] H. Braak,et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.
[131] J. Penney,et al. Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial , 2002, Annals of neurology.
[132] K. Jellinger,et al. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease? , 1999, Life sciences.
[133] A. Schapira. Science, medicine, and the future: Parkinson's disease. , 1999, BMJ.
[134] J C Rothwell,et al. Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.
[135] P. Jenner,et al. Oxidative mechanisms in nigral cell death in Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[136] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[137] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[138] A. Schapira,et al. Oxidative stress in Parkinson's disease , 1995, Neuropathology and applied neurobiology.
[139] C. Marsden,et al. Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.
[140] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[141] J. Juillard. [Parkinson disease]. , 1985, Revue de l'infirmiere.